Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Scancell unveils funding plans for exciting pipeline of next-generation cancer drugs

In a separate announcement, the company said it was acquiring new technology from Nottingham University that will complement its current pipeline
female researcher at microscope
The company has outlined what it plans in the next phase of development

Immunotherapy specialist Scancell Holdings Plc (LONSCLP) has conditionally raised £6.9mln, after expenses, in a discounted placing and share subscription, with the cash to be used develop its three main drug candidates.

The placing and subscription of 57.411mln shares, around 16.7% of the firm's issued share capital, was completed at a price of 12 pence a share, around a 31.4% discount to Wednesday's closing price. In late afternoon trading, Scancell shares were trading at 14p each, a 20% decline.

The company is also undertaking planning a £2mln open offer of stock to include existing investors in the fundraising.

WATCH: Scancell to raise up to £8mln to develop its three main drug candidates

The combined proceeds will be used to fund a phase II trial of the company’s lead drug, SCIB-1, in combination with a checkpoint inhibitor to treat late-stage melanoma.

Cancer Research UK 

Cash will also be deployed to support the Cancer Research UK development of SCIB2 for non-small-cell lung cancer.

And it will be used to begin a first-in-human study of Modi-1 in patients with triple-negative breast cancer, ovarian cancer and sarcoma planned to start in the first-half of next year.

In a separate announcement, Scancell said it had acquired a number of unique monoclonal antibodies to tumour-associated glycans that have the potential, when coupled with a method of activating the immune system, to provide a new class of cancer immunotherapy.

“We believe this platform complements our existing ImmunoBody and Moditope platforms, significantly broadening the strength and potential of Scancell's immunotherapy pipeline," said chief executive Cliff Holloway.

 -- Updates with placing completion details, share price --

View full SCLP profile View Profile

Scancell Holdings Plc Timeline

Newswire
February 08 2018

Related Articles

nizoral shampoo
Tue
The new product will be the company's fourth international star brand
little girl sneezing in a field
May 21 2018
The Phase II study of Allergy Therapeutics’ PQ Grass immunotherapy – an aluminium-free, ultra-short course hay fever treatment – evaluated dose response and safety
scientist looking through a microscope
October 31 2017
As of March, ReNeuron had £53mln in cash equivalents but its market value is not too much above that....

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use